Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351 is registered in ClinicalTrials.gov with Elan Pharmaceuticals as lead sponsor.

NCT NCT01144351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01144351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Elan Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2010
Completion date
Not reported
Enrollment
32 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis